Search results
Results From The WOW.Com Content Network
N-Nitrosodimethylamine (NDMA), also known as dimethylnitrosamine (DMN), is an organic compound with the formula (CH 3) 2 NNO. It is one of the simplest members of a large class of nitrosamines. It is a volatile yellow oil. NDMA has attracted wide attention as being highly hepatotoxic and a known carcinogen in laboratory animals. [2]
NMDA receptor antagonists induce a state called dissociative anesthesia, marked by catalepsy, amnesia, and analgesia. [1] Ketamine is a favored anesthetic for emergency patients with unknown medical history and in the treatment of burn victims because it depresses breathing and circulation less than other anesthetics.
Antagonists of the NMDA receptor are used as anesthetics for animals and sometimes humans, and are often used as recreational drugs due to their hallucinogenic properties, in addition to their unique effects at elevated dosages such as dissociation.
Anti-NMDA receptor encephalitis is a type of brain inflammation caused by antibodies. [4] Early symptoms may include fever, headache, and feeling tired. [1] [2] This is then typically followed by psychosis which presents with false beliefs (delusions) and seeing or hearing things that others do not see or hear (hallucinations). [1]
In 1978, he and David E. Nichols published a report on the drug's psychoactive effect in humans. [227] They described MDMA as inducing "an easily controlled altered state of consciousness with emotional and sensual overtones" comparable "to marijuana, to psilocybin devoid of the hallucinatory component, or to low levels of MDA". [245]
Many of us are painfully aware of our body's increasing number of shortcomings as we get older. Sagging skin, hearing loss, receding hairlines and tending to use the bathroom more frequently than ...
They evaluated the drugs’ effect on a comprehensive catalogue of 175 health outcomes and found that compared with usual care, where people continued use of their regular medications without a ...
NMDA receptor modulators (glutamate modulators) are a new form of antipsychotic that are in Phase II FDA studies. The first compound studied was glycine which was hypothesized by Daniel Javitt after observation that people with phencyclidine(PCP)-induced psychosis were lacking in glutamate transmission. [1]